Merck, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: $295.3B

Website: http://www.merck.ph

Clinical Trials

Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)

Phase 3

Active, not recruiting

Conditions: Papillomavirus Infections

Interventions: Biological: 9vHPV Vaccine
Other: Placebo (Saline for Injection)

First Posted Date: 2019-12-16

Last Posted Date: 2025-03-25

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 6033

Registration Number: NCT04199689

Locations: 🇺🇸
Augusta University ( Site 0010), Augusta, Georgia, United States
🇺🇸
Kentucky Pediatric/Adult Research Inc ( Site 0011), Bardstown, Kentucky, United States
🇺🇸
Preferred Primary Care Physicians ( Site 0032), Pittsburgh, Pennsylvania, United States

and more 100 locations

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)

Phase 3

Completed

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Lenvatinib
Drug: Placebo
Biological: Pembrolizumab

First Posted Date: 2019-12-13

Last Posted Date: 2025-04-23

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 511

Registration Number: NCT04199104

Locations: 🇨🇦
Princess Margaret Cancer Centre ( Site 0200), Toronto, Ontario, Canada
🇺🇸
University of Connecticut Health Center ( Site 0020), Farmington, Connecticut, United States
🇺🇸
Dana Farber Cancer Institute ( Site 0019), Boston, Massachusetts, United States

and more 149 locations

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

Phase 3

Active, not recruiting

Conditions: Carcinoma, Renal Cell

Interventions: Drug: Belzutifan
Drug: Everolimus

First Posted Date: 2019-12-12

Last Posted Date: 2025-04-29

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 755

Registration Number: NCT04195750

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 1514), Baltimore, Maryland, United States
🇺🇸
The University of Chicago Medical Center ( Site 1539), Chicago, Illinois, United States
🇺🇸
Cleveland Clinic ( Site 1504), Cleveland, Ohio, United States

and more 169 locations

Efficacy and Safety of Gefapixant (MK-7264) in Women With Chronic Cough and Stress Urinary Incontinence (MK-7264-042)

Phase 3

Completed

Conditions: Chronic Cough

Interventions: Drug: Placebo
Drug: Gefapixant

First Posted Date: 2019-12-10

Last Posted Date: 2024-11-05

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 376

Registration Number: NCT04193176

Locations: 🇺🇸
Florida Pulmonary Research Institute, LLC ( Site 0008), Winter Park, Florida, United States
🇩🇪
Praxis Dr. Wehgartner-Winkler ( Site 0906), Augsburg, Bayern, Germany
🇷🇺
Medi Kom ( Site 1456), Saint Petersburg, Sankt-Peterburg, Russian Federation

and more 87 locations

V114 and Acute Otitis Media (V114-032/PNEU-ERA)

Phase 3

Active, not recruiting

Conditions: Acute Otitis Media (AOM)

Interventions: Biological: V114
Other: Pediatric vaccines

First Posted Date: 2019-12-10

Last Posted Date: 2025-05-15

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 7000

Registration Number: NCT04193215

Locations: 🇹🇭
Panyananthaphikkhu Chonprathan Medical Center ( Site 0014), Pak Kret, Nonthaburi, Thailand
🇹🇭
Bhumibol Adulyadej Hospital ( Site 0013), Sai Mai, Krung Thep Maha Nakhon, Thailand
🇹🇭
Sappasit Prasong Hosptial-Pediatric ( Site 0016), Ubon Ratchathani, Thailand

and more 10 locations

Efficacy and Safety of Gefapixant (MK-7264) in Adult Participants With Recent Onset Chronic Cough (MK-7264-043)

Phase 3

Completed

Conditions: Chronic Cough

Interventions: Drug: Gefapixant
Drug: Placebo

First Posted Date: 2019-12-10

Last Posted Date: 2023-05-16

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 419

Registration Number: NCT04193202

Locations: 🇬🇹
Clinica Medica Especializada en Neumologia ( Site 0502), Guatemala, Guatemala
🇰🇷
Konkuk University Medical Center ( Site 1504), Seoul, Korea, Republic of
🇰🇷
Severance Hospital Yonsei University Health System ( Site 1503), Seoul, Korea, Republic of

and more 88 locations

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)

Phase 3

Active, not recruiting

Conditions: Metastatic Hormone-Sensitive Prostate Cancer

Interventions: Biological: Pembrolizumab
Drug: Enzalutamide
Drug: Androgen Deprivation Therapy (ADT)
Other: Placebo

First Posted Date: 2019-12-09

Last Posted Date: 2025-05-25

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 1251

Registration Number: NCT04191096

Locations: 🇺🇸
UCLA Hematology/Oncology - Santa Monica ( Site 0241), Los Angeles, California, United States
🇲🇽
Grupo Medico Camino SC ( Site 2613), Mexico City, Mexico
🇩🇪
Klinikum der Universitaet Muenchen - Grosshadern ( Site 1210), Muenchen, Bayern, Germany

and more 210 locations

Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)

Phase 2

Active, not recruiting

Conditions: Triple Negative Breast Neoplasms

Interventions: Biological: Pembrolizumab
Drug: Carboplatin
Drug: Olaparib
Drug: Gemcitabine

First Posted Date: 2019-12-09

Last Posted Date: 2024-11-13

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 462

Registration Number: NCT04191135

Locations: 🇺🇸
University of Chicago ( Site 0159), Chicago, Illinois, United States
🇬🇧
Raigmore Hospital ( Site 0915), Inverness, Highland, United Kingdom
🇺🇦
Zhytomyr Regional Oncology Center ( Site 1515), Zhytomyr, Zhytomyrska Oblast, Ukraine

and more 119 locations

A Phase 1/Phase 2 Study of Polyvalent Pneumococcal Conjugate Vaccine (V116) in Adults (V116-001)

Phase 1

Completed

Conditions: Pneumonia, Pneumococcal

Interventions: Biological: V116
Biological: Pneumovax™23

First Posted Date: 2019-11-19

Last Posted Date: 2022-09-16

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 600

Registration Number: NCT04168190

Locations: 🇺🇸
Central Arizona Medical Associates ( Site 0003), Mesa, Arizona, United States
🇺🇸
Indago Research & Health Center, Inc ( Site 0011), Hialeah, Florida, United States
🇺🇸
Research Centers of America, LLC ( Site 0001), Hollywood, Florida, United States

and more 17 locations

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

Recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Diagnostic Test: Tumor Imaging
Procedure: Tumor Tissue Collection
Procedure: Blood Sample Collection

First Posted Date: 2019-11-18

Last Posted Date: 2025-05-09

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 1065

Registration Number: NCT04165798

Locations: 🇺🇸
UCSF Medical Center at Mission Bay ( Site 0007), San Francisco, California, United States
🇺🇸
Georgetown University ( Site 0036), Washington, District of Columbia, United States
🇺🇸
University of Kentucky Markey Cancer Center ( Site 0019), Lexington, Kentucky, United States

and more 36 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy